Low efficacy of entecavir therapy in adefovir-refractory hepatitis B patients with prior lamivudine resistance
β Scribed by S. W. Cho; K. H. Koh; J. Y. Cheong; M. H. Lee; S. P. Hong; W. D. Yoo; S.-O. Kim
- Book ID
- 108886312
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 68 KB
- Volume
- 17
- Category
- Article
- ISSN
- 1352-0504
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
This study evaluated the efficacy of adefovir (ADV) plus lamivudine (LAM) or ADV add-on therapy for patients with entecavir (ETV)-refractory hepatitis B infection. Twenty-nine ETVresistant and 8 patients with suboptimal response to ETV were enrolled. Twenty-seven patients received ADV ΓΎ LAM therapy
## Abstract There is little clinical information on the management of hepatitis B virus (HBV) that is resistant to multiple drugs including entecavir (ETV). The present retrospective cohort study assessed the antiviral efficacy of ETV/adefovir dipivoxil (ADV) combination therapy for ETVβresistant H
## Abstract No study has reported on the comparative effect of adefovir (ADV) addβon lamivudine (LAM) versus switching to entecavir (ETV) in LAMβresistant patients with chronic hepatitis B. From October 2007 to September 2008, 92 consecutive LAMβresistant patients were enrolled (47 LAMβ+βADV and 45
Entecavir (ETV) is currently recommended as a rescue therapy purely for adefovir (ADV)resistant chronic hepatitis B virus (HBV) infections. We evaluated the efficacy of ETV in patients who were resistant to lamivudine (LAM)/ADV sequential therapy and in those resistant to LAM monotherapy. Fifty LAM/